G. Vega

发表

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

Jonathan C. Cohen, I. Kotowski, A. Pertsemlidis, 2006, American journal of human genetics.

Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels.

Jonathan C. Cohen, S. Grundy, A. Pertsemlidis, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors.

C. Lamendola, S. Grundy, P. Savage, 2002, Circulation.

Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment.

S. Grundy, G. Vega, 1992, Archives of internal medicine.

Evaluation of quantitative models of the effect of insulin on lipolysis and glucose disposal.

Carson C. Chow, R. Bergman, G. Vega, 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults.

A. Khera, C. Ayers, S. Grundy, 2012, JAMA.

An Analysis of Individual Body Fat Depots and Risk of Developing Cancer: INSIGHTS FROM THE DALLAS HEART STUDY

C. Ayers, S. Grundy, G. Vega, 2017, Mayo Clinic proceedings.

Body fat distribution and incident cardiovascular disease in obese adults.

A. Khera, C. Ayers, Anand Rohatgi, 2015, Journal of the American College of Cardiology.

Waist Circumference as Measure of Abdominal Fat Compartments

S. Grundy, G. Vega, I. Neeland, 2013, Journal of obesity.

Sex differences in the association between leptin and CRP: results from the Dallas Heart Study.

A. Khera, S. Grundy, G. Vega, 2007, Atherosclerosis.

Adipose tissue mass and location affect circulating adiponectin levels

A. Khera, C. Ayers, S. Grundy, 2011, Diabetologia.

Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol.

S. Grundy, G. Vega, B. Blades, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

The -514 polymorphism in the hepatic lipase gene (LIPC) does not influence androgen-mediated stimulation of hepatic lipase activity.

S. Grundy, R. Mahley, G. Vega, 1998, Journal of lipid research.

Hepatic lipase activity is lower in African American men than in white American men: effects of 5' flanking polymorphism in the hepatic lipase gene (LIPC).

S. Grundy, G. Vega, L. Clark, 1998, Journal of lipid research.

Hepatic lipase (LIPC) promoter polymorphism in men with coronary artery disease. Allele frequency and effects on hepatic lipase activity and plasma HDL-C concentrations.

J. Cigarroa, S. Grundy, G. Vega, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults

Jarett D. Berry, A. Khera, C. Ayers, 2012, Obesity.

Normal triglyceride levels despite insulin resistance in African Americans: role of lipoprotein lipase.

R. Bergman, G. Vega, R. Boston, 2005, Metabolism: clinical and experimental.

Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome.

S. Grundy, Sidney C. Smith, G. Vega, 2007, American heart journal.

Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease: Risk Enhancing Factors in Intermediate Risk for ASCVD.

S. Grundy, G. Vega, Jijia Wang, 2021, Journal of clinical lipidology.

Triglyceride–to–High-Density-Lipoprotein-Cholesterol Ratio Is an Index of Heart Disease Mortality and of Incidence of Type 2 Diabetes Mellitus in Men

S. Grundy, G. Vega, C. E. Barlow, 2014, Journal of Investigative Medicine.

Influence of Upper and Lower Body Adipose Tissue on Insulin Sensitivity in South Asian Men

S. Grundy, G. Vega, F. Dunn, 2012, Journal of Investigative Medicine.

Current trends in non-HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease.

S. Grundy, G. Vega, 2019, Journal of clinical lipidology.

Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy.

G. Vega, 2004, Endocrinology and metabolism clinics of North America.

Management of Primary Mixed Hyperlipidemia With Lovastatin

S. Grundy, G. Vega, 1990 .

Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia.

S. Grundy, G. Vega, A. Garg, 1990, The American journal of cardiology.

Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics of apolipoprotein B.

S. Grundy, G. Vega, C. East, 1989, Arteriosclerosis.

Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome.

S. Grundy, G. Vega, F. Dunn, 2011, The American journal of cardiology.

The effects of gender and CYP46 and apo E polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients treated with statins.

G. Vega, M. Weiner, H. Kölsch, 2004, Current Alzheimer research.

Does measurement of apolipoprotein B have a place in cholesterol management?

S. Grundy, G. Vega, Scott M. Grundy, 1990, Arteriosclerosis.

Metabolic syndrome is a sequela of radiation exposure in hypothalamic obesity among survivors of childhood brain tumors

G. Vega, L. Klesse, D. Bowers, 2018, Journal of Investigative Medicine.

Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome

S. Grundy, G. Vega, J. Phan, 2017, Journal of the Endocrine Society.

The association of cardiorespiratory fitness, body mass index, and age with testosterone levels at screening of healthy men undergoing preventive medical examinations: The Cooper Center Longitudinal Study.

G. Vega, L. Gibbons, C. E. Barlow, 2018, Maturitas.

Cardiorespiratory fitness and metabolic risk.

S. Grundy, G. Vega, W. Haskell, 2012, The American journal of cardiology.

Association of triglyceride-to-HDL cholesterol ratio to cardiorespiratory fitness in men 61 62 63 64 65

S. Grundy, G. Vega, C. E. Barlow, 2016 .

Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia.

S. Grundy, G. Vega, A. Tall, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia.

S. Grundy, G. Vega, R. Toto, 1995, Kidney international.

Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.

G. Vega, M. Weiner, A. Lipton, 2003, Archives of neurology.

Reduction in Levels of 24 S-Hydroxycholesterol by Statin Treatment in Patients With Alzheimer Disease

G. Vega, M. Weiner, A. Lipton, 2003 .

Quantitation of apolipoprotein B by chemical methods.

S. Grundy, G. Vega, 1996, Methods in enzymology.

Mechanisms of primary hypercholesterolemia in humans.

S. Grundy, G. Vega, 1987, American heart journal.

Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.

S. Grundy, G. Vega, 1987, JAMA.

Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids.

S. Grundy, G. Vega, H. Gylling, 1992, Journal of lipid research.

Causes of High Blood Cholesterol

S. Grundy, G. Vega, 1990, Circulation.

Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population.

S. Grundy, R. Mahley, G. Vega, 1999, Journal of lipid research.

Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men.

S. Grundy, G. Vega, P. Grayburn, 1994, Archives of internal medicine.

Two patterns of LDL metabolism in normotriglyceridemic patients with hypoalphalipoproteinemia.

S. Grundy, G. Vega, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins.

S. Grundy, G. Vega, 1985, JAMA.

Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100.

S. Grundy, G. Vega, N. Abate, 1993, Atherosclerosis.

Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia.

S. Grundy, G. Vega, Scott M. Grundy, 1989, JAMA.

Persistence of abnormalities in metabolism of apolipoproteins B-100 and A-I after weight reduction in patients with primary hypertriglyceridemia.

M. Wilson, S. Grundy, G. Vega, 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

Role of apolipoprotein levels in clinical practice.

S. Grundy, G. Vega, 1990, Archives of internal medicine.

Management of the Hyperlipidemia of the Nephrotic Syndrome

S. Grundy, G. Vega, 1990 .

Influence of lovastatin on concentrations and composition of lipoprotein subfractions.

S. Grundy, G. Vega, S. Nozaki, 1990, Atherosclerosis.

Pathogenesis of hypertriglyceridemia: implications for coronary heart disease and therapy.

S. Grundy, G. Vega, 1988, Advances in experimental medicine and biology.

Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.

S. Grundy, G. Vega, 1985, Journal of lipid research.

Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity.

S. Grundy, G. Vega, J. Cohen, 1998, Journal of lipid research.

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.

S. Grundy, G. Vega, N. Cater, 2003, The American journal of cardiology.

Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM.

S. Grundy, G. Vega, N. Abate, 1995, Atherosclerosis.

Influence of polyunsaturated fats on composition of plasma lipoproteins and apolipoproteins.

S. Grundy, G. Vega, R. Wolf, 1982, Journal of lipid research.

Statin therapy for primary prevention in women: What is the role for coronary artery calcium?

S. Grundy, G. Vega, 2022, Journal of clinical lipidology.

Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia

R. Ross, G. Vega, T. Church, 2012, Pediatric blood & cancer.

Fatty acid oxidation in normotriglyceridemic men.

S. Grundy, G. Vega, Magdalene Szuszkiewicz-Garcia, 2016, Journal of clinical lipidology.

Effects of N-3 Fatty Acids on Hepatic Triglyceride Content in Humans

S. Grundy, G. Vega, M. Chandalia, 2008, Journal of Investigative Medicine.

Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients. Role of cholesterol-ester transfer protein and lecithin cholesteryl acyl transferase.

S. Grundy, G. Vega, F. Tató, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Hypercholesterolemia with cholesterol-enriched LDL and normal levels of LDL-apolipoprotein B. Effects of the step I diet and bile acid sequestrants on the cholesterol content of LDL.

S. Grundy, G. Vega, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy

G. Vega, R. Toto, B. Adams-Huet, 2016, Journal of Investigative Medicine.

Cholesterol Management in Patients with Chronic Kidney Disease

S. Grundy, G. Vega, R. Toto, 2008 .

Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.

S. Grundy, G. Vega, 1998, The American journal of cardiology.

Plasma 24S-hydroxycholesterol and other oxysterols in acute closed head injury

G. Vega, M. Weiner, R. Diaz-Arrastia, 2008, Brain injury.

Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.

S. Grundy, G. Vega, R. Bucala, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Lipoprotein Responses to Treatment with Lovastatin, Gemfibrozil and Nicotinic Acid in Normolipidemic Patients with Hypoalphalipoproteinemia

S. Grundy, G. Vega, 1994 .

Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease

S. Grundy, G. Vega, 1996, Current opinion in lipidology.

Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover.

S. Grundy, R. Uauy, G. Vega, 1988, The Journal of pediatrics.

Plasma 24S Hydroxycholesterol Response to Statins in Alzheimer’s Disease Patients: Effects of Gender, CYP46, and ApoE Polymorphisms

G. Vega, M. Weiner, 2007, Journal of Molecular Neuroscience.

Three polymorphisms associated with low hepatic lipase activity are common in African Americans.

S. Grundy, G. Vega, L. Clark, 1998, Journal of lipid research.

Comparison of apolipoprotein B to cholesterol in low density lipoproteins of patients with coronary heart disease.

S. Grundy, G. Vega, 1984, Journal of lipid research.

Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study.

A. Khera, C. Ayers, S. Grundy, 2012, The Journal of clinical endocrinology and metabolism.

Fibric acids: effects on lipids and lipoprotein metabolism.

S. Grundy, G. Vega, Scott M. Grundy, 1987, The American journal of medicine.

Physiologic levels of ascorbate inhibit the oxidative modification of low density lipoprotein.

S. Grundy, G. Vega, I. Jialal, 1990, Atherosclerosis.

Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B‐containing lipoproteins

R. Krauss, S. Grundy, G. Vega, 1990, Journal of internal medicine.

Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients

G. Vega, R. Rosenberg, L. Hynan, 2003, Neurology.

LIPOPROTEINS OF BIOLOGICAL FLUIDS

G. Vega, P. Roheim, C. H. Sloop, 1981 .

Estimation of turnover of low density lipoproteins by simplified methods.

S. Grundy, G. Vega, 1989, Atherosclerosis.

Kinetic Mechanisms Determining Variability in Low Density Lipoprotein Levels and Rise with Age

S. Grundy, G. Vega, D. Bilheimer, 1985, Arteriosclerosis.

No Association Between Plasma Levels of Plant Sterols and Atherosclerosis in Mice and Men

Jonathan C. Cohen, S. Grundy, G. Vega, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Low density lipoprotein metabolism in hypertriglyceridemic and normolipidemic patients with coronary heart disease.

S. Grundy, G. Vega, W. Beltz, 1985, Journal of lipid research.

13 – Kinetics of Apolipoprotein B in Normal and Hyperlipidemic Man: Review of Current Data

S. Grundy, G. Vega, Y. A. Kesaniemi, 1982 .

Effects of lovastatin on the levels, structure, and atherogenicity of VLDL in patients with moderate hypertriglyceridemia.

W. A. Bradley, S. Grundy, G. Vega, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Occurrence of species of low‐density lipoprotein with defective clearance in patients with primary moderate hypercholesterolaemia

S. Grundy, G. Vega, 1992, Journal of internal medicine.

Coinheritance of two mild defects in low density lipoprotein receptor function produces severe hypercholesterolemia.

S. Grundy, R. Uauy, G. Vega, 1991, The Journal of clinical endocrinology and metabolism.

Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia

S. Grundy, G. Vega, 1991, Journal of internal medicine.

Low density lipoprotein kinetics in a family having defective low density lipoprotein receptors in which hypercholesterolemia is suppressed.

S. Grundy, G. Vega, H. Hobbs, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Increased catabolism of VLDL-apolipoprotein B and synthesis of bile acids in a case of hypobetalipoproteinemia.

S. Grundy, G. Vega, K. von Bergmann, 1987, Metabolism: clinical and experimental.

Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis.

S. Grundy, G. Vega, C. Ballantyne, 1987, Metabolism: clinical and experimental.

Normocholesterolemic tendon xanthomatosis with overproduction of apolipoprotein B.

S. Grundy, G. Vega, D. Illingworth, 1983, Metabolism: clinical and experimental.

Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men. Genetic and pharmacological evidence.

S. Grundy, G. Vega, J. Otvos, 1999, Journal of lipid research.

30 – Metabolism of Apolipoproteins A-I and A-II in Man: Methods, Kinetic Models, and Turnover Rates

S. Grundy, G. Vega, 1982 .

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.

S. Grundy, G. Vega, 1988, Kidney international.

Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia.

S. Grundy, G. Vega, D. Bilheimer, 1985, Annals of internal medicine.

Hypertriglyceridemia: Causes and Relation to Coronary Heart Disease

S. Grundy, G. Vega, Gloria B Vega, 1988, Seminars in thrombosis and hemostasis.

Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins.

R. Krauss, S. Grundy, R. Mahley, 1988, Proceedings of the National Academy of Sciences of the United States of America.

A truncated species of apolipoprotein B, B-83, associated with hypobetalipoproteinemia.

Robert V Farese, G. Vega, S. Young, 1992, Journal of lipid research.

14 – What Is β-VLDL?

S. Grundy, G. Vega, 1982 .

Impaired Hepatic Ketogenesis in Moderately Obese Men With Hypertriglyceridemia

S. Grundy, G. Vega, F. Dunn, 2009, Journal of Investigative Medicine.

Abnormalities in metabolism of low density lipoproteins associated with coronary heart disease.

S. Grundy, G. Vega, Y. Kesäniemi, 2009, Acta medica Scandinavica. Supplementum.

Hypercholesterolemia in postmenopausal women: Metabolic defects and response to low‐dose lovastatin

S. Grundy, G. Vega, M. Arca, 1994, JAMA.

Traditional signs and symptoms commonly attributed to hypogonadism do not correlate with testosterone levels: the Cooper Center Longitudinal Study Experience

G. Vega, L. Gibbons, C. E. Barlow, 2019, Journal of Investigative Medicine.

Temporal decline in non-high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease.

S. Grundy, G. Vega, Jijia Wang, 2020, Journal of clinical lipidology.

Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol

S. Grundy, G. Vega, K. von Bergmann, 1999, Journal of internal medicine.

Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.

S. Grundy, R. Mahley, G. Vega, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels.

S. Grundy, G. Vega, F. Tató, 1996, Archives of internal medicine.

Apolipoproteins in human cerebrospinal fluid.

G. Vega, M. Carey, T. Forte, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia.

S. Grundy, G. Vega, 1994, Archives of internal medicine.

Oxandrolone Enhances Hepatic Ketogenesis in Adult Men

S. Grundy, G. Vega, F. Dunn, 2008, Journal of Investigative Medicine.

19 – Are Plasma Triglyceride Concentrations Explained by Saturation Kinetics?

S. Grundy, G. Vega, 1982 .

Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100.

S. Grundy, G. Vega, H. R. Clarke, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.

S. Grundy, G. Vega, C. East, 1988, Atherosclerosis.

Kinetic Heterogeneity of Low Density Lipoproteins in Primary Hypertriglyceridemia

S. Grundy, G. Vega, 1986, Arteriosclerosis.

Relation of Regional Fat Distribution to Left Ventricular Structure and Function

A. Khera, C. Ayers, M. Drazner, 2013, Circulation. Cardiovascular imaging.

Evaluation of a method for study of kinetics of autologous apolipoprotein A-I.

S. Grundy, G. Vega, H. Gylling, 1991, Journal of lipid research.

Results of Expert Meetings: Obesity and Cardiovascular Disease. Obesity, the metabolic syndrome, and cardiovascular disease.

G. Vega, 2001, American heart journal.

Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.

R. Krauss, S. Grundy, R. Mahley, 1990, Journal of lipid research.

What is meant by overproduction of apo B-containing lipoproteins?

S. Grundy, G. Vega, 1991, Advances in experimental medicine and biology.

Apoproteins of high density lipoproteins in the urine of normal subjects.

G. Vega, P. Segal, H. Eder, 1979, Journal of lipid research.

Mechanisms and treatment of dyslipidemia of renal diseases.

S. Grundy, G. Vega, R. Toto, 1993, Current opinion in nephrology and hypertension.

Comparison of visceral fat mass measurement by dual-X-ray absorptiometry and magnetic resonance imaging in a multiethnic cohort: the Dallas Heart Study

S. Grundy, G. Vega, B. Adams-Huet, 2016, Nutrition & Diabetes.

Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms

M. Longnecker, J. Corton, G. Vega, 2021, Toxicology.

Studies on mechanisms for enhanced clearance of low‐density lipoproteins in patients with primary hypertriglyceridaemia

S. Grundy, G. Vega, 1989, Journal of internal medicine.

Interleukin-18, the Metabolic Syndrome, and Subclinical Atherosclerosis: Results From the Dallas Heart Study

P. Libby, A. Khera, S. Grundy, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Metabolic Risk Susceptibility in Men Is Partially Related to Adiponectin/Leptin Ratio

S. Grundy, G. Vega, 2013, Journal of obesity.

Influence of body fat content and distribution on variation in metabolic risk.

S. Grundy, G. Vega, B. Adams-Huet, 2006, The Journal of clinical endocrinology and metabolism.

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

S. Grundy, G. Vega, W. Brady, 2005, The American journal of cardiology.

Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.

R. Krauss, S. Grundy, R. Mahley, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Efficacy , Safety , and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes

G. Vega, B. Tulloch, R. Rosenson, 2002 .

In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia.

S. Grundy, G. Vega, 1986, The Journal of clinical investigation.

Rationale and management of hyperlipidemia of the nephrotic syndrome.

S. Grundy, G. Vega, 1989, The American journal of medicine.

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

S. Grundy, G. Vega, B. Tulloch, 2002, Archives of internal medicine.

Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia.

S. Grundy, G. Vega, J. Mostaza, 1997, The American journal of cardiology.

Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations.

S. Grundy, G. Vega, F. Tató, 1995, Arteriosclerosis, Thrombosis and Vascular Biology.

Serum Lipids in the GENECARD Study of Coronary Artery Disease Identify Quantitative Trait Loci and Phenotypic Subsets on Chromosomes 3q and 5q

J. Haines, W. Kraus, C. Granger, 2006, Annals of human genetics.

Hepatic lipase: new insights from genetic and metabolic studies.

S. Grundy, G. Vega, J. Cohen, 1999, Current opinion in lipidology.

Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study

Dermot F. Reilly, G. Vega, D. Reilly, 2018, Diabetologia.

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

P. Raskin, G. Vega, Uzma F Mehdi, 2009, Journal of the American Society of Nephrology : JASN.

Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers

A. Atri, J. Growdon, B. Hyman, 2010, Alzheimer disease and associated disorders.

Concentrations of apolipoprotein A-I-containing particles in patients with hypoalphalipoproteinemia.

S. Grundy, G. Vega, A. Montali, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Metabolic Basis of Primary Hypercholesterolemia

S. Grundy, G. Vega, M. Denke, 1991, Circulation.

Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase.

S. Grundy, G. Vega, F. Tató, 1998, The American journal of cardiology.

Management of primary mixed hyperlipidemia with lovastatin.

S. Grundy, G. Vega, 1990, Archives of internal medicine.

Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study.

S. Grundy, G. Vega, Monohar Vajja, 2006, Current therapeutic research, clinical and experimental.

Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).

S. Grundy, G. Vega, J. Tomassini, 2011, The American journal of cardiology.

Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).

S. Grundy, G. Vega, J. Tomassini, 2009, The American journal of cardiology.

African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study.

S. Grundy, G. Vega, H. Hobbs, 2004, Journal of the American College of Cardiology.

Moderate to High Levels of Cardiorespiratory Fitness Attenuate the Effects of Triglyceride to High‐Density Lipoprotein Cholesterol Ratio on Coronary Heart Disease Mortality in Men

G. Vega, W. Haskell, L. Defina, 2017, Mayo Clinic proceedings.

Association of multiple adiposity exposures and cardiorespiratory fitness with all-cause mortality in men: the Cooper Center Longitudinal Study.

G. Vega, J. Morrow, A. Jackson, 2014, Mayo Clinic proceedings.

LDL Phenotype in Subjects with Mild Cognitive Impairment and Alzheimer’s Disease

G. Vega, M. Weiner, Sheikh Vikarunnessa, 2014, Journal of Alzheimer's disease : JAD.

Plasma cholesterol responsiveness to saturated fatty acids.

S. Grundy, G. Vega, Scott M. Grundy, 1988, The American journal of clinical nutrition.

Responsiveness of plasma lipids and lipoproteins to plant stanol esters.

S. Grundy, G. Vega, N. Cater, 2005, The American journal of cardiology.

Impact of Body Mass and Body Composition on Circulating Levels of Natriuretic Peptides: Results From the Dallas Heart Study

M. Drazner, G. Vega, J. D. de Lemos, 2005, Circulation.

Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome

D. Hadizadeh, S. Grundy, G. Vega, 2003, Clinical pharmacology and therapeutics.

Association of urinary sodium-to-potassium ratio with obesity in a multiethnic cohort.

G. Vega, A. Minhajuddin, S. Hedayati, 2014, The American journal of clinical nutrition.

Metabolic correlates of nonalcoholic fatty liver in women and men

S. Grundy, G. Vega, M. Chandalia, 2007, Hepatology.

The multiphasic profile of free fatty acids during the intravenous glucose tolerance test is unresponsive to exogenous insulin.

R. Bergman, G. Vega, R. Watanabe, 2004, Metabolism: clinical and experimental.

Counterpoint: Lipoproteins and dementia: Is there compelling evidence to treat Alzheimer's patients with statins?

P. Wilson, G. Vega, 2008, Journal of clinical lipidology.

Atherogenic low density lipoprotein phenotype in long-term survivors of childhood acute lymphoblastic leukemia

R. Ross, G. Vega, C. Sklar, 2012, Journal of Lipid Research.

Coronary and peripheral artery plaques: do differences in plaque characteristics translate to differences in lipid management?

G. Vega, Shirling Tsai, 2020, Journal of Investigative Medicine.

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men.

S. Grundy, G. Vega, D. Leonard, 2016, Journal of clinical lipidology.

Higher acute insulin response to glucose may determine greater free fatty acid clearance in African-American women.

G. Vega, C. Chow, V. Periwal, 2011, The Journal of clinical endocrinology and metabolism.

Sex differences in the relationship between C-reactive protein and body fat.

A. Khera, C. Ayers, S. Grundy, 2009, The Journal of clinical endocrinology and metabolism.

Ethnic-Specific Criteria for the Metabolic Syndrome

S. Grundy, Sidney C. Smith, G. Vega, 2006, Diabetes Care.

Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile.

A. Khera, C. Ayers, G. Vega, 2013, Journal of the American College of Cardiology.

Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study

A. Khera, C. Ayers, S. Grundy, 2008, Diabetes & vascular disease research.

Pravastatin Treatment of Very Low Density, Intermediate Density and Low Density Lipoproteins in Hypercholesterolemia and Combined Hyperlipidemia Secondary to the Nephrotic Syndrome

S. Grundy, G. Vega, R. Toto, 2000, American Journal of Nephrology.

Ethnic differences in hepatic steatosis: An insulin resistance paradox?

S. Grundy, G. Vega, J. Browning, 2009, Hepatology.

Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia.

R. Ross, G. Vega, A. Dunn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.

Jonathan C. Cohen, S. Grundy, G. Vega, 2010, The Journal of clinical endocrinology and metabolism.

Statin Intolerance and Non-Compliance: An Empiric Approach.

S. Grundy, G. Vega, 2021, The American journal of medicine.

Cardiovascular outcomes for obesity and metabolic syndrome.

G. Vega, 2002, Obesity research.

Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.

S. Grundy, G. Vega, N. Cater, 2005, The American journal of cardiology.

Is There a Role for Coronary Calcium in Patients With Diabetes?

S. Grundy, G. Vega, N. Wong, 2023, The American journal of cardiology.

Upper body fat predicts metabolic syndrome similarly in men and women

S. Grundy, G. Vega, C. Williams, 2018, European journal of clinical investigation.

Prevalence of the metabolic syndrome as influenced by the measure of obesity employed.

S. Grundy, G. Vega, C. Barlow, 2010, The American journal of cardiology.

Variable contributions of fat content and distribution to metabolic syndrome risk factors.

S. Grundy, G. Vega, B. Adams-Huet, 2008, Metabolic syndrome and related disorders.

Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease

S. Grundy, G. Vega, Jijia Wang, 2021 .

Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy.

S. Grundy, G. Vega, 1990, JAMA.

Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease.

S. Grundy, G. Vega, S. Devaraj, 1998, The American journal of medicine.

Variability in Postheparin Hepatic Lipase Activity Is Associated with Plasma Adiponectin Levels in African Americans

G. Vega, B. Adams-Huet, R. Considine, 2007, Journal of Investigative Medicine.

Relationship between Perceptions about Neighborhood Environment and Prevalent Obesity: Data from the Dallas Heart Study

C. Ayers, S. Grundy, G. Vega, 2012, Obesity.

Orthorexia Nervosa and Eating Disorder Symptoms in Registered Dietitian Nutritionists in the United States.

C. McAdams, G. Vega, L. Sandon, 2017, Journal of the Academy of Nutrition and Dietetics.

Apolipoprotein eϵ4, other risk factors, and course of alzheimer’s disease

G. Vega, L. Honig, M. Weiner, 1999, Biological Psychiatry.

Obesity, the metabolic syndrome, and cardiovascular disease

G. Vega, 2001 .

Body size misperception: a novel determinant in the obesity epidemic.

A. Khera, C. Ayers, Anand Rohatgi, 2010, Archives of internal medicine.

Sources of variability in genetic association studies: Insights from the analysis of hepatic lipase (LIPC)

Jonathan C. Cohen, S. Grundy, R. Mahley, 2002, Human mutation.

Postheparin lipolytic activity and plasma lipoprotein response to omega-3 polyunsaturated fatty acids in patients with primary hypertriglyceridemia.

S. Grundy, G. Vega, S. Nozaki, 1991, The American journal of clinical nutrition.

Metabolic syndrome phenotype in very obese women.

S. Grundy, G. Vega, E. Hamilton, 2007, Metabolic syndrome and related disorders.

Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease.

G. Vega, L. Honig, M. Weiner, 1999, Biological psychiatry.

Tumor necrosis factor mediates hypertriglyceridemia during thermal injury in mice genetically susceptible to lipopolysaccharides.

G. Vega, C. Baxter, 1991, Journal of Burn Care and Rehabilitation.

Levels of cofactors for lipoprotein lipase and lecithin-cholesterol acyltransferase in plasma patients with severe thermal injury.

G. Vega, C. Baxter, P. Alaupovic, 1988, The Journal of burn care & rehabilitation.

Induction of hypertriglyceridemia in rabbits by thermal injury: I. Time course of elevated plasma triglyceride levels.

G. Vega, C. Baxter, 1988, The Journal of burn care & rehabilitation.

Statin therapy for primary prevention in men: What is the role for coronary artery calcium?

S. Grundy, G. Vega, Jijia Wang, 2022, Journal of clinical lipidology.

Chronic kidney disease and statin eligibility.

S. Grundy, G. Vega, Jijia Wang, 2020, Journal of clinical lipidology.

Is non-high-density lipoprotein cholesterol a marker and therapeutic target for dyslipidemia in metabolic syndrome?

G. Vega, 2014, Metabolic syndrome and related disorders.

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

P. Raskin, G. Vega, Uzma F Mehdi, 2009, Journal of the American Society of Nephrology : JASN.

Association of multiple adiposity exposures and cardiorespiratory fitness with all-cause mortality in men: the Cooper Center Longitudinal Study.

G. Vega, J. Morrow, A. Jackson, 2014, Mayo Clinic proceedings.

Effects of N-3 Fatty Acids on Hepatic Triglyceride Content in Humans

S. Grundy, G. Vega, M. Chandalia, 2008, Journal of Investigative Medicine.

Ethnic and gender susceptibility to metabolic risk.

S. Grundy, G. Vega, I. Neeland, 2014, Metabolic syndrome and related disorders.

Effect of Intensive Diabetes Treatment on Low-Density Lipoprotein Apolipoprotein B Kinetics in Type I Diabetes

P. Raskin, G. Vega, J. Rosenstock, 1988, Diabetes.

Impaired Hepatic Ketogenesis in Moderately Obese Men With Hypertriglyceridemia

S. Grundy, G. Vega, F. Dunn, 2009, Journal of Investigative Medicine.

Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors.

C. Lamendola, S. Grundy, P. Savage, 2002, Circulation.

study in elderly adults Measurement of fat mass using DEXA: a validation

Maren S Fragala, Thuy-Tien L. Dam, D. Kiel, 2015 .

Utility of metabolic syndrome as a risk enhancing factor in decision of statin use.

S. Grundy, G. Vega, Jijia Wang, 2021, Journal of clinical lipidology.

Fasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes

S. Grundy, G. Vega, D. Leonard, 2012, Journal of Investigative Medicine.